Study: Long-term treatment with nonsteroidal mineralocorticoid receptor antagonist finerenone estimated to extend event-free survival by up to 3 years among people with heart failure with mildly reduced or preserved ejection fraction.
Read Full Article
#HeartFailure #Finerenone #EventFreeSurvival #EjectionFraction #HeartHealth
Read Full Article
#HeartFailure #Finerenone #EventFreeSurvival #EjectionFraction #HeartHealth
EurekAlert!
Estimated long-term benefits of finerenone in heart failure
About The Study: In this prespecified secondary analysis of the FINEARTS-HF randomized clinical trial, long-term treatment with the nonsteroidal mineralocorticoid receptor antagonist finerenone was estimated to extend event-free survival by up to 3 years…